Literature DB >> 2930717

Phase I study of 21 days continuous infusion with vindesine.

E G de Vries1, E F Smit, D E Vendrig, J J Holthuis, N H Mulder.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2930717      PMCID： PMC2247064          DOI： 10.1038/bjc.1989.97

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  11 in total

1.  Clinical pharmacokinetics of vindesine infusion.

Authors:  R Rahmani; J P Kleisbauer; J P Cano; M Martin; J Barbet
Journal:  Cancer Treat Rep       Date:  1985 Jul-Aug

2.  Analysis of vinca alkaloids in plasma and urine using high-performance liquid chromatography with electrochemical detection.

Authors:  D E Vendrig; J Teeuwsen; J J Holthuis
Journal:  J Chromatogr       Date:  1988-01-22

Review 3.  Continuous infusion or bolus injection in cancer chemotherapy.

Authors:  R W Carlson; B I Sikic
Journal:  Ann Intern Med       Date:  1983-12       Impact factor: 25.391

4.  A phase I and pharmacokinetic study with 21-day continuous infusion of epirubicin.

Authors:  E G de Vries; J Greidanus; N H Mulder; M B Nieweg; P E Postmus; D L Schipper; D T Sleijfer; D R Uges; P H Willemse
Journal:  J Clin Oncol       Date:  1987-09       Impact factor: 44.544

5.  Treatment of advanced non-Hodgkin's lymphoma with vincristine infusion.

Authors:  D V Jackson; E H Paschold; C L Spurr; H B Muss; F Richards; M R Cooper; D R White; J J Stuart; J O Hopkins; R Rich
Journal:  Cancer       Date:  1984-06-15       Impact factor: 6.860

6.  Vindesine in the treatment of refractory breast cancer: improvement in therapeutic index with continuous 5-day infusion.

Authors:  H Y Yap; G R Blumenschein; G P Bodey; G N Hortobagyi; A U Buzdar; A DiStefano
Journal:  Cancer Treat Rep       Date:  1981 Sep-Oct

7.  Protracted vinblastine infusion. Phase I-II study in malignant melanoma and other tumors.

Authors:  J J Lokich; T E Zipoli; J Perri; A Bothe
Journal:  Am J Clin Oncol       Date:  1984-10       Impact factor: 2.339

8.  Phase II clinical trial with vindesine for remission induction in acute leukemia, blastic crisis of chronic myeloid leukemia, lymphosarcoma, and hodgkin's disease: absence of cross-resistance with vincristine.

Authors:  G Mathé; J L Misset; F De Vassal; J Gouveia; M Hayat; D Machover; D Belpomme; J L Pico; L Schwarzenberg; P Ribaud; M Musset; C Jasmin; L De Luca
Journal:  Cancer Treat Rep       Date:  1978-05

9.  Evaluation of a totally implanted venous access port and portable pump in a continuous chemotherapy infusion schedule on an outpatient basis.

Authors:  J Greidanus; E G de Vries; M B Nieweg; Z J de Langen; P H Willemse
Journal:  Eur J Cancer Clin Oncol       Date:  1987-11

10.  Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules.

Authors:  R J Gralla; E S Casper; D P Kelsen; D W Braun; M E Dukeman; N Martini; C W Young; R B Golbey
Journal:  Ann Intern Med       Date:  1981-10       Impact factor: 25.391
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.